Aquinox recognizes the value of effectively protecting its intellectual property and core technologies and believes that existing and continual patent development forms the foundation of that protection. The company is uniquely positioned through exclusive licenses to strong patents and has a diverse drug portfolio to develop products that regulate the PI3K pathway through SHIP and related enzymes.